Al-OlaAAbdallahMD

Oncology • Westwood, KS

Hematologic Oncology

Physician

Join to view full profile

Dr. Abdallah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abdallah's full profile

Already have an account?

Office
2650 Shawnee Mission Pkwy
Ms 5003
Westwood, KS 66205
Phone+1 913-588-6078

Fax+1 913-588-3996

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2016
University of Oklahoma School of Community Medicine (Tulsa)Residency, Internal Medicine, 2007 - 2010
University of Jordan Faculty of MedicineClass of 2005

Certifications & Licensure

AR State Medical License 2011 - 2026
KS State Medical License 2016 - 2025
MO State Medical License 2021 - 2025
OK State Medical License 2009 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Publications & Presentations

PubMed

9 citations
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
Tommy Etekal, Kelly Koehn, Douglas W Sborov, Brian McClune, Vinay Prasad
British Journal of Haematology. 2023-03-01
98 citations
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka
Cancer. 2021-07-27
40 citations
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Paul G. Richardson, Hans C. Lee, Al-Ola Abdallah, Adam D. Cohen, Prashant Kapoor
Blood Cancer Journal. 2020-10-23

Lectures

SGNBCMA-001: A phase 1 study of SEA‑BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019